Showing results (611-620 of 776) with videos related to
Sort By:
Pageof 78
The Journal of Dermatological Treatment|April 18, 2012
Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot studyTina Bhutani, Faranak Kamangar, Kristine Zitelli, et al.Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|November 6, 2008
Cooperative robot assistant for retinal microsurgeryIoana Fleming, Marcin Balicki, John Koo, et al.The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.The Journal of Dermatological Treatment|October 5, 2010
Improving clinical trial design in psoriasis: Perspectives from the global dermatology communityPeter van de Kerkhof, Jonathan Barker, Christopher E M Griffiths, et al.Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.Dermatology and Therapy|February 7, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis TrialsJoseph F Merola, Laura K Ferris, Jeffrey M Sobell, et al.The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.Pageof 78